All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub is pleased to present a visual abstract representing key data from a phase II clinical trial (NCT03383575) evaluating enasidenib, both in combination with azacitidine and as monotherapy in patients with high-risk IDH2-mutated MDS. The safety and efficacy of enasidenib has been previously reported by the MDS Hub.
To download this visual abstract, click below.Download here
Your opinion matters
Safety and efficacy of enasidenib in IDH2-mutated myelodysplastic syndrome
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor approved by the U.S. Food and Drug Administration in 2017 for treating adult patients with relapsed/refractory...
Practice-changing abstracts at EHA 2020
The MDS Hub was pleased to speak to Steering Committee Chair Theo De Witte, Radboudumc, Nijmegen, NL, about practice-changing abstracts from the 25th European Hematology Association (EHA) Annual Congress.
Subscribe to get the best content related to MDS delivered to your inbox